Study drug B001 for neuromyelitis optic spectrum disorder attacks
Part of Brain & nervous system, Eyes & vision, Immune system & allergy clinical trials.
This early-phase study tests B001 injection to see if it can help people with neuromyelitis optica spectrum disorder (NMOSD) who have had recent relapses. It may be aimed at reducing future attacks and improving disability over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have NMOSD confirmed by 2015 criteria and you test positive for anti-AQP4 antibodies
- You had at least one documented relapse/flare in the past 12 months
- Your disability score (EDSS) is between 0 and 7.5 at screening
- You are age 18 to 70 when you sign consent
- You have not taken certain NMOSD/MS relapse-prevention or immune-related medicines recently (timing limits apply)
- You do not have recent serious infection, pregnancy/breastfeeding, active hepatitis B/C, active tuberculosis, or dangerous lab abnormalities
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational drug called B001 for people with NMOSD who have had recent relapses. The goal is to see if it can reduce future flare-ups.
This trial tests whether an investigational drug called KSVCBD can safely reduce relapses in people with neuromyelitis optica spectrum disorder (NMOSD). If you have had at least one relapse in the past year and meet other criteria, you may be able to join.
This study looks at treatments for people with neuromyelitis optica spectrum disorder (NMOSD) who are having a sudden attack affecting their vision or spinal cord. It aims to find out which treatments work best in everyday practice.
This study tests whether a low dose of a protein called IL-2 can safely help control the immune system in people with neuromyelitis optica spectrum disorder (NMOSD). It aims to reduce disease activity and improve symptoms.
This study tests a new medicine called ravulizumab (an infusion) to reduce relapses in people with neuromyelitis optica spectrum disorder (NMOSD), a rare condition affecting the optic nerve and spinal cord. The trial is specifically enrolling adults in China who have had recent disease activity.
This trial tests a new treatment called modified zipper therapy for people with neuromyelitis optica spectrum disorder (NMOSD) who have a specific antibody (AQP4-IgG) in their blood. It aims to stop a recent attack and improve recovery.
Hear when a new NMO Spectrum Disorder trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.